Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma
Jong-Yun Woo, Seung Ho Yang, Youn Soo Lee, Su Youn Lee, Jeana Kim, Yong Kil Hong
J Korean Neurosurg Soc. 2015;58(5):426-431.   Published online 2015 Nov 30     DOI: https://doi.org/10.3340/jkns.2015.58.5.426
Citations to this article as recorded by Crossref logo
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma
Heinrich Elinzano, Steven Toms, Jordan Robison, Alex Mohler, Arieana Carcieri, Deus Cielo, Jennifer Donnelly, Dylan Disano, John Vatketich, John Baekey, Ashlee Sturtevant, Kelsey MacKinnon, Roxanne Wood, Howard Safran
American Journal of Clinical Oncology.2021; 44(2): 49.     CrossRef
CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer
Yun Lin, Zhi Li, Mubiao Liu, Haiyan Ye, Jianhui He, Jianguo Chen
Archives of Gynecology and Obstetrics.2021; 304(2): 495.     CrossRef
Histopathological investigation of the 1p/19q-codeleted gliomas resected following alkylating agent chemotherapy
Tokunori Kanazawa, Kentaro Ohara, Yohei Kitamura, Masato Nakaya, Kazunari Yoshida, Hikaru Sasaki
Journal of Neuro-Oncology.2021; 155(3): 235.     CrossRef
Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism
Catherine A.A. Lee, Pallavi Banerjee, Brian J. Wilson, Siyuan Wu, Qin Guo, Gretchen Berg, Svetlana Karpova, Ananda Mishra, John W. Lian, Johnathan Tran, Max Emmerich, George F. Murphy, Markus H. Frank, Natasha Y. Frank
Journal of Biological Chemistry.2020; 295(22): 7774.     CrossRef
Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity
Bryan J. Neth, Michael W. Ruff, Joon H. Uhm, Derek R. Johnson, Rohit D. Divekar, Daniel E. Maddox
Cancer Chemotherapy and Pharmacology.2020; 86(3): 375.     CrossRef
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
Cem Simsek, Ece Esin, Suayib Yalcin
Journal of Oncology.2019; 2019: 1.     CrossRef
Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
Salvatore Tafuto, Claudia von Arx, Monica Capozzi, Fabiana Tatangelo, Manuela Mura, Roberta Modica, Maria Luisa Barretta, Antonella Di Sarno, Maria Lina Tornesello, Annamaria Colao, Alessandro Ottaiano
Journal of Clinical Medicine.2019; 8(8): 1224.     CrossRef
Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation
Se-Hyuk Kim, Heon Yoo, Jong Hee Chang, Chae-Yong Kim, Dong Sup Chung, Se Hoon Kim, Sung-Hae Park, Youn Soo Lee, Seung Ho Yang
Journal of Korean Medical Science.2018;[Epub]     CrossRef
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma
Zhengqiu Zhou, Tracy A. Howard, John L. Villano
Cancer Chemotherapy and Pharmacology.2017; 80(5): 1043.     CrossRef